MDT

100.26

+3%↑

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

MDT

100.26

+3%↑

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

MDT

100.26

+3%↑

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

MDT

100.26

+3%↑

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

MDT

100.26

+3%↑

147.57

+3.37%↑

VEEV

238.01

+7.61%↑

HQY

94.97

+1.71%↑

PHR.US

17.21

+0.53%↑

Kodu・Aktsiate loetelu・Gossamer Bio Inc

Gossamer Bio Inc

Suletud

SektorTervishoid

2.55 -6.59

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.52

Max

2.73

Põhinäitajad
By Trading Economics
Sissetulek	-9.9M -48M
Müük	1.8M 13M
Kasumimarginaal	-362.728
Töötajad	144
EBITDA	-10M -45M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+350% upside

Turustatistika
By TradingEconomics
Turukapital	87M 634M
Eelmine avamishind	9.14
Eelmine sulgemishind	2.55

Uudiste sentiment

By Acuity

60%

40%

332 / 373 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

1.06 / 1.23 Toetus ja vastupanu

Gossamer Bio Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

6. jaan 2026, 21:14 UTC

Suurimad hinnamuutused turgudel

Ventyx Biosciences Gains on Report of Possible $1 Billion Eli Lilly Deal

6. jaan 2026, 19:23 UTC

Omandamised, ülevõtmised, äriostud

OneStream to Go Private Through $6.4 Billion Hg Acquisition

6. jaan 2026, 17:41 UTC

Suurimad hinnamuutused turgudel

Blink Charging Shares Rise as EV Chargers Begin Accepting Cryptocurrency

6. jaan 2026, 15:46 UTC

Omandamised, ülevõtmised, äriostud

Advent International Leads InPost Takeover Offer, Sky News Says

6. jaan 2026, 15:37 UTC

Suurimad hinnamuutused turgudel

Terrestrial Energy Shares Rise After DOE Agreement For Nuclear Plant Development

6. jaan 2026, 23:46 UTC

Market Talk

Nikkei May Decline After Hitting Record High -- Market Talk

6. jaan 2026, 23:35 UTC

Market Talk

Gold Edges Higher Amid Ongoing Geopolitical Tensions -- Market Talk

6. jaan 2026, 23:19 UTC

Market Talk

Greatland 2Q Gold Output Strong, Sales Soft -- Market Talk

6. jaan 2026, 22:53 UTC

Market Talk

WiseTech, REA and CAR Look Best Insulated From AI Threat -- Market Talk

6. jaan 2026, 22:03 UTC

Omandamised, ülevõtmised, äriostud

Staar Surgical: Merger Proposal Received 14.9M Votes For and 27.3M Against

6. jaan 2026, 22:03 UTC

Omandamised, ülevõtmised, äriostud

Staar Surgical, Which Earlier Reported Stockholder Rejection of Sale to Alcon, Reports Vote Totals

6. jaan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

6. jaan 2026, 21:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6. jaan 2026, 21:12 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

6. jaan 2026, 21:12 UTC

Market Talk

Commodity Demand Helps Canada Reduce Reliance on Trade With U.S. -- Market Talk

6. jaan 2026, 20:59 UTC

Suurimad hinnamuutused turgudel

Omandamised, ülevõtmised, äriostud

Ventyx Biosciences Gains on Report of Possible $1B Eli Lilly Deal

6. jaan 2026, 20:40 UTC

Omandamised, ülevõtmised, äriostud

Acquisition of Ventyx Would Bring Lilly Into Emerging Category of Pills for Inflammation-Related Conditions -- WSJ

6. jaan 2026, 20:40 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly Nears Deal for Biotech Ventyx -- WSJ

6. jaan 2026, 20:40 UTC

Omandamised, ülevõtmised, äriostud

Deal Could Be Announced Imminently, Sources Say -- WSJ

6. jaan 2026, 20:40 UTC

Omandamised, ülevõtmised, äriostud

Eli Lilly in Advanced Talks to Buy Ventyx Biosciences For Over $1B, Sources Say -- WSJ

6. jaan 2026, 20:01 UTC

Market Talk

Oil Futures Give Back Post-Venezuela Incursion Gains -- Market Talk

6. jaan 2026, 19:52 UTC

Market Talk

U.S. Natural Gas Falls Awaiting Colder Weather -- Market Talk

6. jaan 2026, 19:46 UTC

Omandamised, ülevõtmised, äriostud

Under Armour Stock Rises After the 'Warren Buffet of Canada' Boosts Its Stake -- Barrons.com

6. jaan 2026, 19:08 UTC

Omandamised, ülevõtmised, äriostud

OneStream to Go Private Through $6.4B Hg Acquisition

6. jaan 2026, 18:28 UTC

Omandamised, ülevõtmised, äriostud

These Stocks Are Moving the Most Today: Sandisk, Nvidia, AMD, Palantir, OneStream, SoFi, Microchip, and More -- Barrons.com

6. jaan 2026, 17:20 UTC

Market Talk

Tulu

Financial Services Roundup: Market Talk

6. jaan 2026, 17:20 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Health Care Roundup: Market Talk

6. jaan 2026, 15:57 UTC

Market Talk

Crude Futures Ease Back From Early Gains -- Market Talk

6. jaan 2026, 15:34 UTC

Market Talk

Tulu

Bank of Montreal Expects to Exit 2027 With ROE Hitting 15% Target -- Market Talk

6. jaan 2026, 15:27 UTC

Market Talk

German Inflation Won't Fall Much Further in 2026 -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Gossamer Bio Inc Prognoos

Hinnasiht

By TipRanks

350% tõus

12 kuu keskmine prognoos

Keskmine 12.33 USD 350%

Kõrge 15 USD

Madal 10 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Gossamer Bio Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

4 ratings

Osta

Hoia

Müü

Põhineb 4 analüütiku instrumendi Gossamer Bio Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.06 / 1.23Toetus ja vastupanu

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

332 / 373 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.